Grail Gets $300M More For Cancer Detection Testing
Menlo Park-based Grail, which is developing DNA-based, blood testing technology to detect cancer, has raised $300M more in funding, the company said this week. The funding came from Ally Bridge Group, Hillhouse Capital, 6 Dimensions Capital, Blue Pool Capital, China Merchant Securities International, CRF Investment, HuangPu River Capital, ICBC International, Sequoia Capital China and WuXi NextCODE. The startup, led by CEO Jennifer Cook, is a spinout of Illumina.
posted on Friday, May 25, 2018 (Link to more information)
Related companies:
GRAIL
Related stories:
> Grail Nears $1 Billion In Series B
> GRAIL Raises $900M For Cancer Detection Efforts
> 23andMe Gets $300M From GlaxoSmithKline
> Veracyte Gets $28M
> Color Genomics Captures $45M For Genetic Testing For Cancer Risk
silicontap.com Home